Nephrology

This week's highlight includes phase 3 trial results across dermatology, cardiology, and pulmonology, and a major conference preview.

Mohamad Hussain, MD, PhD, discusses Phase 3 findings on Humacyte's bioengineered vessel and its potential role in vascular access for women on dialysis.

Dana Rizk, MD, joins hosts Brendon Neuen and Shikha Wadhwani to unpack 2-year VISIONARY data showing sibeprenlimab stabilizes eGFR in IgAN.

Brad Rovin, MD, discusses persistent gaps in IgA nephropathy diagnosis and treatment, from RAS inhibition limits to the promise of B-cell-targeted therapies.

Matthew Breeggemann, MD, of UCSF discusses genetic testing, risk stratification, and the future of personalized CKD management in 2026.

Stay updated with the latest healthcare breakthroughs, including phase 3 sibeprenlimab data in IgAN and the FDA approval of oveporexton for narcolepsy.

Sibeprenlimab (Voyxact) achieves KDIGO goal, stabilizing eGFR decline in IgA nephropathy at 2-year Phase 3 VISIONARY readout.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia and the FDA approval of Furoscix ReadyFlow.

Nephrology in July 2026: FDA approvals for atacicept, iptacopan, and Furoscix in IgAN/CKD, plus new IgAN and CKD trial data.

The IL-6 inhibitor missed its primary MACE endpoint in ASCVD, CKD, and inflammation despite expected biological effect on target engagement.

Nephrology experts discuss how CKD care has evolved in 2026, including SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, and personalized treatment.

Andrew Adams discusses tegoprubart in kidney transplantation and the phase 2 BESTOW data on kidney function, rejection, and immunosuppression.

Ramy Hanna, MD, discusses early IgAN recognition, biopsy decisions, and how emerging therapies are reshaping disease management.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia, the FDA approval of Furoscix ReadyFlow, and more.

The approval makes MannKind Corporation’s furosemide injection the first and only autoinjector delivering SC furosemide with IV-equivalent exposure.

IgA nephropathy shows a male predominance, but researchers have not identified why. Ramy Hanna, MD explores possible biological explanations.

Richard Lafayette, MD, discusses how atacicept's FDA approval advances BAFF/APRIL targeting in IgA nephropathy.

Stay updated with the latest healthcare breakthroughs, including FDA approvals, phase 3 data, and open-label extension results.

ORIGIN 3 investigator brings atacicept approval to BAFF/APRIL targeting to IgAN

Marc Richards, MD, discusses how new therapies and combination treatment strategies are transforming evidence-based care for chronic kidney disease.

Michael Richards, MD, discusses aldosterone's role in CKD pathophysiology and why targeting this pathway may reshape kidney disease treatment.

The FDA granted traditional approval to Novartis’ iptacopan (Fabhalta) for adults with primary IgA nephropathy, supported by phase 3 APPLAUSE-IgAN data showing slowed kidney function decline and sustained proteinuria reductions.

NYU Langone’s Conor Donnelly, Allan Massie, and Michal Mankowski explain why follow-up after kidney transplant referral is critical to improving access.

Phase 3 FIND-CKD data show finerenone slows kidney decline and reduces CV events in adults with nondiabetic CKD, Rajiv Agarwal, MD, adds his perspective.

Massie, Donnelly, and Mankowski discuss how transplant center choice shapes kidney transplant evaluation and access.